Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinovac Reports 39% Higher 2008 Revenues

publication date: Apr 10, 2009

Sinovac Biotech (北京科兴生物制品有限公司) reported that revenues from its vaccines rose 39% in 2008 to $46.5 million, while net income increased by a relatively small 5% to $8 million. A full 88% of the company’s 2008 sales came from Healive®, its hepatitis A vaccine that has long been Sinovac’s mainstay product. Sinovac said it expects 2009 revenues to increase a further 20% to a range of $55 million to $60 million. More details...

Stock Symbol: (NYSE Amex: SVA)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here